Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both osteosarcoma cell lines have retained major functions of normal osteoblasts; principally, the capacity to produce hematopoietic growth factors (including IL-6) and osteocalcin, a noncollagenic protein essential in the bone formation process.
|
7579410 |
1995 |
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine the molecular basis of this effect, we analyzed the human IL-6 promoter fused (-1,179 to +9) with the chloramphenicol acetyltransferase (CAT) reporter gene in stable transfections into human osteoblast-like osteosarcoma SaOS-2 cells.
|
9328832 |
1997 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Competitive RT-PCR and Ala-pNA activity assays revealed that IL-6 and sIL-6R significantly increased the mRNA expression and activity of APN in both osteosarcoma cell lines.
|
11089884 |
1999 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Northern analysis demonstrated that in the osteosarcoma cell lines there was no regulation of syndecan transcript levels in response to PTH(1-34) or 1,25(OH)2-vitamin D3 for 24 or 48 h. In contrast, when MG-63 and SaOS-2 cells were incubated with IL-1beta (0.01-10 ng/mL) and IL-6 (0.1-50 ng/mL) there was a dose-dependent decrease in mRNA levels for syndecan-1 and -2 at 24 and 48 h, but in response to IL-1beta upregulation in the levels of syndecan-4 transcripts.
|
10375199 |
1999 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we tested the hypothesis that TNF-alpha-induced IL-6 production in MG-63 osteosarcoma cells occurs via the p38 mitogen-activated protein kinase (MAPK) pathway.
|
11820362 |
2002 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data showed that primarily IGF-1, TGF beta 1 and IL-6 (up to 25 ng/ml for 48 h) increased PTHrP mRNA expression and modified its perinuclear localization, while zoledronic acid (up to 100 microM for 48 h) inhibited cell proliferation and suppressed PTHrP expression in the MG-63 osteosarcoma cells.
|
16475708 |
2006 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using human MCF-7 breast carcinoma and G-292 osteosarcoma cell lines, it was investigated whether the phytoestrogens genistein and daidzein affect reporter gene transcription via the estrogen receptors (ERs) ERalpha and ERbeta1 as well as whether they affect the expression of estrogen-responsive genes in MCF-7 cells and the secretion of the cytokine IL-6 from G-292 cells.
|
17266178 |
2007 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human mesenchymal stem cells promote growth of osteosarcoma: involvement of interleukin-6 in the interaction between human mesenchymal stem cells and Saos-2.
|
20874851 |
2010 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to further determine the effect of IL-6/STAT3 signaling on the progression of osteosarcoma.
|
22743617 |
2012 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, knockdown IL-6 reduced VEGF expression and abolished osteosarcoma conditional medium-mediated angiogenesis.
|
23219526 |
2013 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice lacking IL-6 or NKT cells had accelerated development of IR-induced osteosarcomas.
|
24231354 |
2013 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also elucidated that Interleukin 6 (IL-6) increases ADAMTS-2 and ADAMTS-3 mRNA and protein levels in different osteosarcoma cell lines namely, MG-63 and Saos-2.
|
24752352 |
2014 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously, we demonstrated that tumour self-seeding by CTCs occurs in osteosarcoma and revealed that interleukin-6 (IL-6) may promote CTC attraction.
|
26623559 |
2016 |
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The IL-6 -174 G/C genotype was associated with risk for development and metastasis of osteosarcoma in Chinese Han population.
|
26810186 |
2016 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It suggested that up regulation of IL-6 mediated visfatin induced in vitro motility of osteosarcoma cells.
|
27568842 |
2016 |
Osteosarcoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In addition, irisin suppressed the IL-6-activated phosphorylation of STAT3 and the expression of Snail in osteosarcoma cells.
|
29048621 |
2017 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, H<sup>+</sup> -MSC conditioned medium differentially promoted OS stemness (sarcosphere number, stem-associated gene expression), and chemoresistance also via IL6 secretion.
|
27888521 |
2017 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A positive correlation between the mRNA levels of IL-6 and SOX18 was observed in osteosarcoma tissues.
|
29184419 |
2017 |
Osteosarcoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In vitro, depletion of SH3GL1 abrogates P130<sup>cas</sup> phosphorylation and IL-6- and VEGF-induced OS cell proliferation and migration.
|
28702842 |
2017 |
Osteosarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IL-6 174G/C polymorphism was obviously associated with OS risk in Asians, while TNF-α 238G/A polymorphism seemed to be associated with the decreased susceptibility to OS in Caucasians as Altman and Bland test indicated.
|
29228633 |
2017 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we isolated pure populations of EVs from serum and demonstrated that circulating levels of EV-associated TGFβ are increased in osteosarcoma patients.<b>Conclusions:</b> Collectively, our findings suggest that TEMSCs promote osteosarcoma progression and provide the basis for testing IL6- and TGFβ-blocking agents as new therapeutic options for osteosarcoma patients.<i></i>.
|
28053020 |
2017 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we employ Raman spectroscopy to the identification and discrimination of osteosarcoma cells from osteo-differentiated mesenchymal stromal cells (MSCs) by detecting the presence of HA and IL-6.
|
30523881 |
2018 |
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TET2 knockdown in OS cells suppressed upregulation of IL-6 and demethylation of its promoter in xenograft tumors and decreased tumor metastasis.
|
29515232 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results identify IL-6 and CXCL8 as primary mediators of OS lung tropism and suggest pleiotropic, redundant mechanisms by which they might effect metastasis.
|
30135299 |
2018 |
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TIMP3 Overexpression Improves the Sensitivity of Osteosarcoma to Cisplatin by Reducing IL-6 Production.
|
29731768 |
2018 |